Glutathione Injections

Glutathione injections in brief

Three numbers frame glutathione injections: how fast the body clears it, what the one controlled skin trial found, and what was in the vials that sent people to hospital.

Every figure on this page is taken from a PubMed abstract or from a regulator's published notice, all listed at the end. Glutathione doses are quoted only where a trial abstract or the FDA states them; how people in gyms describe using the injectable is reported as their description, not as a protocol.

What this glutathione injections guide covers

What is glutathione, and is it a peptide?

Before glutathione injections make sense, the molecule needs a paragraph. Glutathione is a tripeptide made of three amino acids, cysteine, glycine and glutamate, and it functions as the major antioxidant of human cells; it is synthesised inside the body, protects the thiol groups of proteins from oxidation, and takes part in the detoxification reactions that keep the cell environment stable (PMID 25378941). It is the most abundant endogenous antioxidant and a critical regulator of oxidative stress and immune function (PMID 24791752).

So the answer to the question people type into search boxes is yes: glutathione is a peptide, the shortest kind, three residues long, which is why it appears under types of peptides on this site next to molecules ten times its size.

Two forms matter. Reduced glutathione, written GSH, is the working antioxidant; when it donates an electron it pairs up into oxidised glutathione, GSSG, and the ratio between the two is what laboratories use as a readout of oxidative stress in blood (PMID 21875351). Nearly all of the body's glutathione is intracellular. Plasma carries very little, about 6 micromoles per litre in one set of healthy volunteers (PMID 1362956), which is the first clue to why an injection behaves the way it does: a vein is not where the molecule normally lives or works.

Glutathione injections come in three shapes. In hospitals, reduced glutathione for injection is a licensed drug in several countries and is given intravenously, typically as a sodium salt, in oncology and cardiology protocols (PMID 39242322, PMID 37374173). In the United States no glutathione injection is FDA approved; what clinics and IV bars administer is compounded from bulk powder, and what research vendors ship is lyophilised powder in vials that the buyer reconstitutes with bacteriostatic water, the same operation the peptide calculator is built for. The three kinds of glutathione injections are the same molecule with three different levels of quality control, and the section on side effects shows what happens when the wrong powder ends up in a syringe.

What is measured on glutathione injections, and in whom

Glutathione injections have a longer research history than most peptides sold online, but almost all of it is in patients receiving chemotherapy, in neurology, or in cardiology, and almost none of it is in the people who now buy it. The table sorts every source on this page by what it can support. The green rows are the only ones that compare glutathione against a placebo.

Read the route column against the weight column. Every placebo-controlled win for glutathione injections or pills is either oral, topical, or an intravenous protocol wrapped around chemotherapy or a contrast dye. Glutathione injections on their own, given to healthy people for a cosmetic or wellness reason, have one controlled trial and it did not reach significance. That is the shape of the evidence, and the rest of the page stays inside it.

What a glutathione injection does in the blood

The pharmacokinetic study that every discussion of glutathione injections should start from was published in 1991. Ten healthy volunteers received 2 g per square metre of body surface as an intravenous infusion; total plasma glutathione rose from 17.5 to 823 micromoles per litre, the volume of distribution was 176 millilitres per kilogram, and the elimination half-life was 14.1 minutes (PMID 1907548). Plasma cysteine rose from 8.9 to 114 micromoles per litre while total cysteine plus cystine in plasma fell, which the authors read as cells pulling cysteine in; urinary glutathione excretion rose 300-fold and cystine excretion 10-fold in the following 90 minutes (PMID 1907548).

Two conclusions follow. First, glutathione injections are a spike: within an hour most of the peptide is either broken into its amino acids or in the bladder. Second, what the injection actually delivers to tissues is cysteine, the rate-limiting building block of the glutathione that cells make for themselves (PMID 1907548). That is the mechanism by which the intravenous drug protects against cisplatin, and it is also why oral cysteine donors such as whey protein and N-acetylcysteine keep appearing in the same conversation.

The oral route is where the story of glutathione injections turns. A single 3 g dose in seven volunteers did not raise plasma glutathione at all over 270 minutes (PMID 1362956), and a four-week trial of 500 mg twice daily in 40 healthy adults changed neither erythrocyte glutathione nor urinary markers of oxidative stress (PMID 21875351).

But the longest trial found the opposite: 54 non-smoking adults randomised to 250 or 1,000 mg daily for six months raised their glutathione by 30 to 35 percent in erythrocytes, plasma and lymphocytes and by 260 percent in buccal cells at the high dose, with a doubling of natural killer cell cytotoxicity at three months, and levels returned to baseline after a one-month washout (PMID 24791752). A pilot of liposomal glutathione at 500 or 1,000 mg daily in 12 adults reported increases of up to 40 percent in whole blood and 100 percent in mononuclear cells after two weeks, without a placebo group (PMID 28853742).

Put together, the data say that blood glutathione can be raised slowly by mouth over months, raised within two weeks by a precursor such as 45 g of whey protein daily in people who are deficient (PMID 11168457), or raised for a few minutes by glutathione injections. Whether any of those changes in a blood compartment translate to the skin, the liver or a muscle is the question the next three sections answer with what exists.

Glutathione injections for skin whitening: what the trials found

Skin lightening is the reason most glutathione injections are sold, and the mechanism is real: glutathione inhibits tyrosinase directly and indirectly and shifts melanin synthesis from dark eumelanin toward lighter pheomelanin (PMID 27088927). The clinical question behind glutathione injections for skin is whether that mechanism, delivered by a needle, changes skin colour more than a placebo.

A 2025 systematic review in the International Journal of Dermatology answered it for each route. Five randomised trials and one open-label study of oral glutathione at 250 mg once a day, 250 mg twice a day or 500 mg once a day showed a significant reduction in melanin index against placebo (PMID 39444151); topical 0.5 percent beat 0.1 percent and placebo; combining 2 percent topical with oral was superior to either. There was only one placebo-controlled study of the intravenous route, with 6 of 16 responders against 3 of 16, p equal to 0.054, and the reviewers concluded that intravenous glutathione is contraindicated because of the lack of efficacy and side effects (PMID 39444151).

The pattern across the table is consistent: oral and topical glutathione produce small, measurable, reversible reductions in melanin index, mostly on sun-exposed skin, and the intravenous route has one trial that did not reach significance. Two earlier reviews of glutathione injections had already said as much.

Sonthalia and colleagues wrote in 2016 that although intravenous glutathione injections are popular there is no evidence to prove their efficacy, and that the adverse effects caused by intravenous glutathione led the Food and Drug Administration of the Philippines to issue a public warning condemning its use for off-label indications such as skin lightening (PMID 27088927). A South African review the same year found no studies of intravenous glutathione for skin lightening at all, no studies of chronic intravenous use for any indication, and raised a mechanism-based concern of its own: the switch from brown to red melanin may increase the risk of sun-induced skin cancer in people whose skin had been protected (PMID 27499402).

An evidence-based case report from Indonesia adds the line on glutathione injections that separates the routes on safety: across three randomised trials, glutathione was well tolerated in oral preparations but not in parenteral ones, and the reviewers judged it not beneficial enough as a whitening agent because the effect was limited to some body parts and did not last (PMID 32373172).

The most recent narrative review, which is the first result Google returns for glutathione injections, reaches the same conclusion from the other side: oral administration shows significant but variable decreases in melanin with limited side effects, while intravenous glutathione, although rapid, is associated with serious safety concerns such as anaphylaxis and hepatotoxicity, made worse by the lack of standardised dosing (PMID 40013212).

The medical intravenous trials: where glutathione injection doses come from

Every real dose of glutathione injections in the literature comes from medicine, not cosmetics, and the two fields use the drug for the same reason: to load cells with cysteine before an oxidative insult. The strongest trial of glutathione injections is in oncology. Fifty patients with advanced gastric cancer on weekly cisplatin were randomised to glutathione or saline; the glutathione arm received 1.5 g per square metre intravenously over 15 minutes immediately before cisplatin and 600 mg by intramuscular injection on days 2 to 5 (PMID 7799029).

After 15 weeks, 4 of 24 assessable patients on glutathione had neuropathy against 16 of 18 on placebo, p equal to 0.0001; nerve conduction fell in the placebo arm but not the glutathione arm; the glutathione group needed fewer transfusions, 32 against 62, and had a higher response rate, 76 against 52 percent, so the antioxidant did not blunt the chemotherapy (PMID 7799029). Those are the glutathione injection benefits that exist in a randomised trial, and they belong to cancer patients.

Cardiology supplies the second set of glutathione injections data. In 21 patients with reduced kidney function undergoing coronary angiography, glutathione at 100 mg per minute for 30 minutes before the procedure completely abolished the rise in urinary lipid hydroperoxides that reached 299.5 percent of baseline in controls, while oral N-acetylcysteine only blunted it to 196.8 percent (PMID 21127883). A randomised subgroup analysis of 100 heart attack patients given glutathione sodium salt infusions before angioplasty and at 24, 48 and 72 hours found contrast-associated acute kidney injury in 5 of 50 against 19 of 50 on placebo, 10 against 38 percent (PMID 37374173).

Neurology is where the hope for glutathione injections was highest and the controlled result the flattest. An open-label study in nine patients with early Parkinson's disease gave 600 mg intravenously twice daily for 30 days and reported a 42 percent decline in disability that lasted two to four months after stopping (PMID 8938817).

The randomised, double-blind follow-up gave 1,400 mg intravenously three times a week for four weeks to 11 patients against 10 on placebo: glutathione was well tolerated, adverse events were similar in both groups, and there were no significant differences in Unified Parkinson's Disease Rating Scale scores, with a 2.8-point difference in the glutathione direction during treatment, p equal to 0.32, and a 3.5-point difference in the wrong direction over the following eight weeks, p equal to 0.54 (PMID 19230029).

Two features of that table matter for anyone reading it as a guide to glutathione injections. Every controlled dose is intravenous and large, gram-scale, given over minutes by staff, with a half-life that makes a single injection a 15-minute event (PMID 1907548). And the intramuscular 600 mg in the cisplatin trial is the only intramuscular dose of glutathione injections in a randomised trial anywhere on this page, given as a follow-on to a 1.5 g per square metre infusion, in cancer patients, for four days (PMID 7799029). No trial has given glutathione subcutaneously to anyone.

Glutathione injections in the gym: how people describe using them, and what is measured

This is the section on glutathione injections that the literature cannot write, so the page reports two things separately: how users and the vendors who sell to them describe glutathione injections in practice, and the small amount of exercise data that exists. Nothing in the first half is evidence; it is a description of a pattern, and the rule of the site is that a pattern people describe is not a dose anyone should copy.

What users describe. On bodybuilding forums and in research-vendor guides glutathione injections are sold as lyophilised powder, typically in 600 mg or 1,200 mg vials, and the guides describe reconstituting a 600 mg vial with 3 ml of bacteriostatic water to get 200 mg per ml, or with 6 ml for 100 mg per ml (vendor guide). The use those guides and forum threads describe is 200 to 400 mg drawn from that vial and injected subcutaneously or intramuscularly, usually into the shoulder or the abdomen, two or three times a week, in blocks of a few weeks (vendor guide, forum posts).

The reasons users give for glutathione injections are consistent: users describe running it during cycles of oral steroids as what they call liver support, alongside N-acetylcysteine or tauroursodeoxycholic acid; they describe it after a cycle as a way to, in their words, clear out; and a smaller group describe weekly intravenous drips of 600 to 2,000 mg bought at IV bars for recovery, skin and jet lag (vendor guide, forum posts). Older bodybuilding sites describe an oral version instead, 100 mg of glutathione inside a multi-ingredient support supplement taken daily on cycle (bodybuilding site).

What the reasons rest on. The liver-support case for glutathione injections borrows from medicine, where the intravenous drug is licensed in some countries as a hepatoprotectant and appears in oncology and cardiology protocols (PMID 39242322, PMID 37374173), but no study has given glutathione by any route to a person taking an oral anabolic steroid, and the hepatotoxicity of those drugs is a different mechanism from the oxidative injury glutathione was tested against; what has been measured about steroids and the liver is on do steroids damage your liver.

The detox case for glutathione injections rests on glutathione's role in cellular detoxification reactions (PMID 25378941), which is a description of an enzyme system, not a trial showing that injecting the peptide speeds anything up. The recovery idea has one small human study behind it, and it was oral.

None of the glutathione injection benefits that users describe, liver, detox or recovery, has been measured in a trial of the injectable.

What is measured in exercise. Eight healthy men aged about 36 took 1 g of oral glutathione or placebo daily for two weeks in a double-blind crossover, then cycled for 60 minutes at 40 percent of maximal heart rate; blood lactate after exercise was 2.9 millimoles per litre on glutathione against 3.4 on placebo and fatigue-related psychological scores were lower (PMID 25685110).

The mouse arm of the same study showed less muscle acidification and higher mitochondrial markers (PMID 25685110). That is the whole of the exercise literature relevant to glutathione injections: eight men, a low-intensity ride, an oral dose, and a half-millimole difference in lactate. A three-week randomised trial of 1,000 mg oral glutathione daily in 20 obese men with and without type 2 diabetes measured insulin sensitivity with the clamp technique and skeletal muscle glutathione by biopsy (PMID 33740389), which is the closest anyone has come to asking what the supplement does inside a muscle.

The honest summary for a lifter is short. The glutathione injections users describe are a route with no pharmacokinetic study, at doses a fifth to a tenth of the medical ones, for reasons that have not been tested, using a powder whose quality is the subject of the next section. The oral trials say blood glutathione can be raised over months by mouth (PMID 24791752) and that a cysteine-rich protein raises it within two weeks in people who are low (PMID 11168457), which is not a case for the needle. How to tell research-chemical marketing from a trial is on peptide research vs human use.

Glutathione injection side effects by the evidence

Glutathione injection side effects come from three places: the molecule, the route, and the powder. The molecule itself was well tolerated at gram-scale intravenous doses in every controlled medical trial on this page; adverse events were similar to placebo in the Parkinson's trial (PMID 19230029) and glutathione did not reduce the effect of chemotherapy (PMID 7799029). The route and the powder are where the recorded harm sits.

The honest summary of glutathione injection side effects is that the peptide itself has behaved well in supervised trials at doses far above what clinics use, and that the recorded harm has come from what was in the vial and from giving a hospital drug outside a hospital. That distinction is not comfort for a home user of glutathione injections; a research vendor's vial is exactly the supplement-grade powder the FDA was writing about, with no endotoxin test between the bag and the syringe. The general page on peptide side effects covers the injection-site and sterility problems shared by every reconstituted peptide.

Injectable vs oral vs NAC vs glutamine: what the head-to-head data show

Four comparisons come up in every search around glutathione injections, and each has at least one measurement behind it. The claimed glutathione injection benefits over pills rest on the first of them.

NAC vs glutathione. N-acetylcysteine is an oral cysteine donor, so it feeds the same synthesis that an intravenous glutathione dose feeds by a different door. The one direct comparison is in kidney protection: before coronary angiography, intravenous glutathione abolished the rise in urinary lipid peroxides, which reached 299.5 percent of baseline in controls, while oral N-acetylcysteine left it at 196.8 percent and did not prevent the fall in serum glutathione (PMID 21127883). In 21 patients that is a win for glutathione injections over the pill for an acute insult, and it says nothing about weeks of oral use.

Glutamine vs glutathione. They are different molecules with similar names. Glutamine is a single amino acid; glutathione is a tripeptide whose glutamate residue can be derived from glutamine, but the limiting ingredient for making glutathione is cysteine, which is why the intravenous drug raises plasma cysteine 13-fold (PMID 1907548) and why cysteine-rich whey protein raised plasma glutathione 44 percent in two weeks in deficient patients (PMID 11168457). No trial compares glutamine with glutathione on any outcome.

Liposomal glutathione. The pilot data are the most impressive numbers on the page, up to 40 percent in whole blood and 100 percent in mononuclear cells within two weeks, but they come from 12 people with no placebo group and no difference between doses (PMID 28853742). The six-month placebo-controlled trial of plain oral glutathione remains the better evidence (PMID 24791752). Which of these belongs in a supplement stack, if any, is a question for health support supplements, which ranks what has trial data.

Five mistakes people make about glutathione injections

Each of these comes from reading a mechanism as if it were a trial, or a clinic menu of glutathione injections as if it were a label.

1. Assuming glutathione injections last. The half-life of intravenous glutathione in healthy volunteers was 14.1 minutes and urinary excretion rose 300-fold in the following 90 minutes (PMID 1907548). A weekly drip is a weekly 15-minute spike.

2. Citing the medical trials of glutathione injections as evidence for cosmetic or gym use. The cisplatin trial gave 1.5 g per square metre intravenously plus 600 mg intramuscularly to cancer patients before a nerve-damaging drug (PMID 7799029). Its result says nothing about the 200 mg under the skin that forum posts describe in a healthy person.

3. Believing glutathione injections beat oral for skin. The controlled data say the opposite: five oral randomised trials lowered the melanin index, the single intravenous trial did not reach significance, and the reviewers called the intravenous route contraindicated (PMID 39444151).

4. Treating the powder as interchangeable. The 2019 cluster of chills, vomiting and hypotension came from supplement-grade L-glutathione with up to five times the endotoxin limit, repackaged for injection (FDA compounding alert, 2019). A research-vendor vial has the same provenance and no test.

5. Mixing glutathione injections into a drip with everything else. Reduced glutathione for injection was physically incompatible with 11 of 44 intravenous drugs at the Y-site (PMID 39242322); the vitamin and NAD cocktails sold alongside it have not been tested with it.

Verdict: a real hospital drug, a weak cosmetic, and an untested gym habit

Glutathione injections, after the abstracts rather than the clinic menus, are a licensed intravenous drug in some countries with a real record in oncology and cardiology, where gram-scale infusions before cisplatin cut neuropathy from 16 of 18 patients to 4 of 24 (PMID 7799029) and infusions around angioplasty cut contrast kidney injury from 38 to 10 percent (PMID 37374173). Outside those settings the record thins fast: no effect on Parkinson's motor scores in the one controlled trial (PMID 19230029), one non-significant skin trial and a reviewers' verdict of contraindicated (PMID 39444151), two regulatory warnings, and a molecule that is gone from plasma in minutes (PMID 1907548).

For readers here the practical conclusion on glutathione injections is that the oral route has the placebo-controlled data the injectable lacks, that the reasons users give for injecting it have never been tested, and that the only recorded harm has come from the powder and the setting rather than the peptide. The arithmetic of a vial is on the peptide calculator; the reason to be careful with any reconstituted peptide is on peptide side effects; and the wider class is on what are peptides.